Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic

Shanghai Heartcare IPO: Thoughts on First Day Trading

Broncus Holdings IPO: Say No to Lung Diseases

Medlive Technology IPO: Forecasts and Valuation

Zylox-Tonbridge IPO: Comprehensive Coverage, Proven Marketing and Core Products Show Good Potential

Zylox-Tonbridge IPO: DCF Valuation Offers Decent Upside to the Upper End

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Medlive Tech IPO (Part II): Further Room for Margin Expansion with Expanding Scale

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Shanghai HeartCare Medical Technology / Equity Capital Markets

Shanghai HeartCare Medical Technology (6609 HK)

<p><a href="https://www.smartkarma.com/entities/shanghai-heartcare-medical-technology-corporation-limited" target="_blank" data-smartkarma-citation="entities:32192:1" rel="noopener">Shanghai HeartCare Medical Technology (HMT HK)</a>  is a neuro-interventional medical device company in China. The company has a pipeline of 23 products of which three were launched in 2020 and have generated revenues of RMB 14.5m. The company has filed for an IPO to list its shares on the Hong Kong Stock Exchange.</p><p>The company’s core product: Captor, has strong potential to capture the market given its favourable performance at clinical trials and its comparatively lower pricing while the other core product LAA Occluder also has showed strong success rates at clinical trials. China’s neuro-interventional medical device market is poised for growth, which would allow the company to grow through the portfolio of new products that it has planned to introduce during the next few years.</p>

Shanghai HeartCare Medical Technology (HMT HK)  is a neuro-interventional medical device company in China. The company has a pipeline of 23 products of which three were launched in 2020 and have generated revenues of RMB 14.5m. The company has filed for an IPO to list its shares on the Hong Kong Stock Exchange.The company’s core product: Captor, has strong potential to capture the market given its favourable performance at clinical trials and its comparatively lower pricing while the other core product LAA Occluder also has showed strong success rates at clinical trials. China’s neuro-interventional medical device market is poised for growth, which would allow the company to grow through the portfolio of new products that it has planned to introduce during the next few years.

Zylox-Tonbridge Medical Technology (2190 HK)

Shanghai Heartcare IPO: Strong Potential in Treating Strokes